NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00265031,HD12 for Advanced Stages,https://clinicaltrials.gov/study/NCT00265031,,COMPLETED,"This study is designed to test (1) whether the BEACOPP dosage can be reduced to baseline in the last 4 cycles without loss of effectiveness, and (2) whether consolidating irradiation is necessary following effective chemotherapy.",NO,HodgkinÂ´s Lymphoma,DRUG: Cyclophosphamide|DRUG: Adriamycin|DRUG: Etoposide|DRUG: Procarbazine|DRUG: Prednisone|DRUG: Vincristine|DRUG: Bleomycin|PROCEDURE: radiation therapy,,,,University of Cologne,,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: TREATMENT,HD12,1999-01,,,2005-12-13,,2012-06-25,,
